Afamelanotide for treating erythropoietic protoporphyria
Afamelanotide for treating erythropoietic protoporphyria
The company submission (CS) presents evidence of the clinical and cost effectiveness of afamelanotide (SCENESSE®) for adult patients with erythropoietic protoporphyria (EPP) above the age of 18 years old compared to best supportive care. In all studies afamelanotide (16 mg) was given as a subcutaneous implant. The main outcomes measured were duration of tolerance to sunlight and other forms of visible light, phototoxic reactions, health related quality of life (HRQoL) and adverse effects (AEs) of treatment.
erythropoietic protoporphyria
National Institute for Health and Care Research
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Gaisford, Wendy C.
f1f37a2e-d281-4577-8332-fef0f8b2c789
Rose, Micah J.
f6deee44-f21f-4d14-90a9-f7a449d0adba
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
26 October 2017
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Onyimadu, Oluchukwu
ff168bd7-1c4f-4756-a34a-7e6b930ae29b
Gaisford, Wendy C.
f1f37a2e-d281-4577-8332-fef0f8b2c789
Rose, Micah J.
f6deee44-f21f-4d14-90a9-f7a449d0adba
Frampton, Geoffrey
26c6163c-3428-45b8-b8b9-92091ff6c69f
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Lord, Joanne, Onyimadu, Oluchukwu, Gaisford, Wendy C., Rose, Micah J., Frampton, Geoffrey and Shepherd, Jonathan
(2017)
Afamelanotide for treating erythropoietic protoporphyria
(Health Technology Assessment, HTA - 16/27/02)
Southampton.
National Institute for Health and Care Research
136pp.
Record type:
Monograph
(Project Report)
Abstract
The company submission (CS) presents evidence of the clinical and cost effectiveness of afamelanotide (SCENESSE®) for adult patients with erythropoietic protoporphyria (EPP) above the age of 18 years old compared to best supportive care. In all studies afamelanotide (16 mg) was given as a subcutaneous implant. The main outcomes measured were duration of tolerance to sunlight and other forms of visible light, phototoxic reactions, health related quality of life (HRQoL) and adverse effects (AEs) of treatment.
Text
Afamelanotide for treating erythropoietic proroporphyria - Evidence Review Group Report
- Version of Record
Text
Afamelanotide for treating erythropoietic proroporphyria - Addendum
- Version of Record
More information
Published date: 26 October 2017
Keywords:
erythropoietic protoporphyria
Identifiers
Local EPrints ID: 417747
URI: http://eprints.soton.ac.uk/id/eprint/417747
PURE UUID: cf37ba59-7c4a-4ed0-95ea-34843c38efe7
Catalogue record
Date deposited: 13 Feb 2018 17:30
Last modified: 22 Aug 2024 01:47
Export record
Contributors
Author:
Wendy C. Gaisford
Author:
Micah J. Rose
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics